Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS...

Health On Cloud, a trailblazer in advanced healthcare solutions, has announced its global expansion strategy, launching its ground-breaking metaverse medical consultation platform, CURISALL, and...

DUBLIN–(BUSINESS WIRE)–The “USA Solid Tumor Therapeutics Market Outlook to 2028” report has been added to ResearchAndMarkets.com’s offering. The USA Solid Tumor Therapeutics Market refers to...

SHANGHAI, Dec 23, 2023 - (ACN Newswire) - ChemPartner, a global leader in drug discovery and development services, today announced the launch of its...

Heidelberg, Germany, Dec 22, 2023 - (ACN Newswire) - BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking...

Medical physicists at University Hospitals Birmingham in the UK rely on LAP’s RadCalc QA secondary check software to support their high-dose-rate...

SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual...

Pharma giant AstraZeneca has signed a $247 million deal with Ai drug creation company Absci to develop an antibody designed to fight cancer. The collaboration...

Company Announces Core Leadership Team, Led by CEO, Kerry L. Blanchard, MD, PhD SHANGHAI & BOSTON–(BUSINESS WIRE)–Perpetual Medicines today announced it has closed an $8...

Exclusive arrangement will expand market access to Personalis’ ultra-sensitive MRD test FREMONT, Calif. & CHICAGO–(BUSINESS WIRE)–Personalis, Inc., a leader in advanced genomics for precision oncology...

The Company announces a new identity for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD), and business unit. iBiopsy® becomes eyonis™. eyonis™ brand...

AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD” Median’s teams will be at booth #4465, South Hall Level 3, to present the latest...